These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 32270407)

  • 1. Rimegepant: First Approval.
    Scott LJ
    Drugs; 2020 May; 80(7):741-746. PubMed ID: 32270407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rimegepant Orally Disintegrating Tablet for Acute Migraine Treatment: A Review.
    DeFalco AP; Lazim R; Cope NE
    Ann Pharmacother; 2021 May; 55(5):650-657. PubMed ID: 32909437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rimegepant (Nurtec ODT) for Acute Treatment of Migraine.
    JAMA; 2020 Sep; 324(9):890-891. PubMed ID: 32870296
    [No Abstract]   [Full Text] [Related]  

  • 4. Rimegepant (Nurtec ODT) for acute treatment of migraine.
    Med Lett Drugs Ther; 2020 May; 62(1597):70-72. PubMed ID: 32555113
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.
    Croop R; Goadsby PJ; Stock DA; Conway CM; Forshaw M; Stock EG; Coric V; Lipton RB
    Lancet; 2019 Aug; 394(10200):737-745. PubMed ID: 31311674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rimegepant for the treatment of migraine.
    Negro A; Martelletti P
    Drugs Today (Barc); 2020 Dec; 56(12):769-780. PubMed ID: 33332483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eptinezumab: First Approval.
    Dhillon S
    Drugs; 2020 May; 80(7):733-739. PubMed ID: 32266704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine.
    Blair HA
    CNS Drugs; 2023 Mar; 37(3):255-265. PubMed ID: 36739335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ubrogepant: First Approval.
    Scott LJ
    Drugs; 2020 Feb; 80(3):323-328. PubMed ID: 32020557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine.
    Lipton RB; Croop R; Stock EG; Stock DA; Morris BA; Frost M; Dubowchik GM; Conway CM; Coric V; Goadsby PJ
    N Engl J Med; 2019 Jul; 381(2):142-149. PubMed ID: 31291516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
    Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
    Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rimegepant: acute treatment for migraine headaches.
    Peters GL; Hennessey EK
    Pain Manag; 2021 May; 11(3):259-266. PubMed ID: 33550872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
    Hargreaves R; Olesen J
    Headache; 2019 Jun; 59(6):951-970. PubMed ID: 31020659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy.
    Mullin K; Kudrow D; Croop R; Lovegren M; Conway CM; Coric V; Lipton RB
    Neurology; 2020 May; 94(20):e2121-e2125. PubMed ID: 31932515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atogepant: First Approval.
    Deeks ED
    Drugs; 2022 Jan; 82(1):65-70. PubMed ID: 34813050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial.
    Croop R; Lipton RB; Kudrow D; Stock DA; Kamen L; Conway CM; Stock EG; Coric V; Goadsby PJ
    Lancet; 2021 Jan; 397(10268):51-60. PubMed ID: 33338437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lasmiditan: First Approval.
    Lamb YN
    Drugs; 2019 Dec; 79(18):1989-1996. PubMed ID: 31749059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating rimegepant for the treatment of migraine.
    de Vries T; Al-Hassany L; MaassenVanDenBrink A
    Expert Opin Pharmacother; 2021 Jun; 22(8):973-979. PubMed ID: 33648385
    [No Abstract]   [Full Text] [Related]  

  • 20. Foreword: The CGRP Pathway and Migraine Prevention: Reducing the Burden of Disease.
    Holland PR
    Headache; 2018 May; 58 Suppl 1():1-3. PubMed ID: 29697155
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.